

10-4-01

A

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
Pha-1626Total Pages in this Submission  
97**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**A Method of Sequencing**

and invented by:

**Allan Asp and Peder Carstenius**If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 09/068,783

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.:

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.:

Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 11 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☒ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☒ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
Pha-1626

Total Pages in this Submission  
97

## Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets \_\_\_\_\_
- b. ☒ Informal Number of Sheets 2
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☒ Paper Copy
- b. ☒ Computer Readable Copy (identical to computer copy)
- c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8. ☒ Assignment Papers (cover sheet & document(s)) 607
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing

☐ First Class ☒ Express Mail (Specify Label No.): EL717698404US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
Pha-1626

Total Pages in this Submission  
97

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. ☐ Additional Enclosures *(please identify below):*

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

***An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.***

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

Pha-1626

Total Pages in this Submission


97

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	2	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$740.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$740.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **500-588** as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of **\$740.00** as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

  
Signature

Royal N. Ronning, Jr.  
Amersham Pharmacia Biotech, Inc.  
800 Centennial Avenue  
Piscataway, New Jersey 08855

Dated: October 3, 2001

(732) 457-8423  
Reg. No.: 32,529

cc:

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): A. Asp, et al.

Docket No.

Pha-1626

Serial No.  
To be assignedFiling Date  
October 3, 2001Examiner  
To be assignedGroup Art Unit  
To be assigned


Invention: A Method of Sequencing

I hereby certify that the following correspondence:

4 page transmittal letter with copy, fee, specification (9 pages), claims (2 pages), drawings (2 pages), First Preliminary Amendment, Submission of Sequence Listing with required statements, sequence listing (paper and diskette copies), copy of Declaration and recorded Assignment from parent case, Information Disclosure Statementt with references, and a return postcard

*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

October 3, 2001*(Date)*Melissa Leck*(Typed or Printed Name of Person Mailing Correspondence)*  
*(Signature of Person Mailing Correspondence)*EL717698404US*("Express Mail" Mailing Label Number)*

Applicant(s): Asp, et al.

Pha-1626

09/068,783

22 February 1999

D. Johannsen

1655

**Invention: A Method of Sequencing**

(Date)

(Typed or Printed Name of Person Mailing Correspondence)

  
(Signature of Person Mailing Correspondence)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: A. Asp, et al. Group Art Unit: To be assigned  
Serial Number: To be assigned Examiner: To be assigned  
Filing Date: October 3, 2001  
Title: A Method of Sequencing

**SUBMISSION OF NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents  
Box New Patent Application  
Washington, D.C. 20231

Dear Sir:


In connection with the prosecution of the captioned application, Applicants submit the following items:

- 1) An initial computer readable form (CFR) copy of the sequence listing and an initial paper copy of the sequence listing, both generated on an IBM computer using PatentIn, Version 2.1 Software.
- 2) Required statements:
  - A. Applicants aver that the sequence listings do not include any new matter which goes beyond the content of the application as filed.
  - B. Applicants aver that that sequence listings contained on the diskette are identical to those contained on the paper copy.

Please direct any issues to Applicant's counsel at the telephone number provided below.

Amersham Pharmacia Biotech, Inc.  
P.O. Box 1327  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327  
(732)457-8423 (voice)  
(732)457-8463 (facsimile)

Respectfully submitted,

  
Royal N. Ronning, Jr.  
Reg. No. 32,529